Results for tag: "Polatuzumab Vedotin"

Polatuzumab vedotin is a monoclonal antibody-drug conjugate (ADC) used to treat certain types of non-Hodgkin lymphoma (NHL). It is a targeted therapy that combines an antibody with a chemotherapy drug, allowing it to be delivered directly to cancer cells. The antibody binds to a protein called CD79b, which is found on the surface of B-cells, a type of white blood cell that is affected by NHL. The chemotherapy drug is then released, killing the cancer cells. Polatuzumab vedotin is approved for use in combination with bendamustine and rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It is also being studied in clinical trials for other types of NHL, including follicular lymphoma and mantle cell lymphoma. The market for polatuzumab vedotin is expected to grow in the coming years as more clinical trials are conducted and the drug is approved for use in additional indications. Companies involved in the market include Genentech, a subsidiary of Roche, and Seattle Genetics, the developer of the drug. Show Less Read more